Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing and advancing innovative ketamine and other innovative treatments for people living with depression and related mental health disorders, is pleased to announce today the opening of its newest Braxia Health clinic in the Kitchener-Waterloo area in Ontario. The Kitchen-waterloo location is the fifth Braxia Health Clinic in Canada.
Braxia’s group of clinics, led by top researchers in depression Dr. Roger McIntyre and Dr. Joshua Rosenblat – as determined by Expertscape – and now Braxia Health Kitchener-Waterloo, provide patients greater access to Braxia’s network of physicians, specialists and researchers delivering innovative, rapid acting treatments like intravenous (IV) and oral ketamine, and psilocybin for treatment resistant depression (TRD) and other mental health disorders. Braxia Health clinics are also delivering world-class patient experience built around global best practices guidelines led by Dr. McIntrye and Dr. Rosenblat in the American Journal of Psychiatry.
“Today’s announcement is the first of what we intend to be a series of growth developments and acquisitions to our clinical network,” “Further plans are in place for the expansion of Braxia Health clinics in Toronto and Ottawa, Ont., to better serve the growing unmet need in our Canadian communities.
Braxia CEO Dr. Roger McIntyre
Kevin Kratiuk, Braxia’s Vice-President of Operations, added, “While Braxia has been managing the patient volumes to date and ensuring care is delivered in a timely manner, an infrastructure expansion was needed to better support our communities and address the unmet burden of treatment-resistant depression. With our new clinic and future expansion plans for our existing clinics, we will also offer more convenient access to treatment for new and existing patients.”
Additionally, Braxia Health clinics have begun to expand current offerings across its centers to include IV and oral ketamine. Braxia specialists have delivered psilocybin treatments to patients through its ongoing multi-dose clinical trial – first-ever Health Canada approved multi-dose psilocybin trial – and, in conjunction with Health Canada special access program (SAP) allowing psilocybin to be prescribed by physicians on a case-by-case basis to patients in need. Braxia was successful in receiving its first psilocybin SAP approval for a patient in Ontario in June 2022 and has now received several additional SAP approvals. To date, Braxia has treated multiple patients with psilocybin through its ongoing multi-dose clinical trial and training of 20 therapists via the Braxia Institute for psilocybin assisted therapy.
Canadians interested in applying to the SAP, to participate in clinical trials or to qualify for other treatments, such as IV and oral Ketamine for the treatment of depression, may contact the medical team at Braxia Health at www.braxiahealth.com.
About Braxia Scientific Corp.
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Kitchener-Waterloo, Ottawa, and Montreal.